CAMPBELLVILLE, ON, June 4 /CNW/ - NIR Diagnostics Inc. (TSX Venture:
NID), an innovator in the development of in-vitro and in-vivo medical
diagnostic devices today announced that it has successfully completed internal
testing of its in-vivo light-based platform for an application that monitors
levels of omega-6 and omega-3 fatty acids non-invasively. The portable
OmegaNIR(TM) device has been developed on the Company's VisionNIR(TM) platform
which allows a user to monitor blood and tissue with the use of near-infrared
light. This eliminates the need to secure a blood sample for expensive and
time consuming laboratory tests. NIR Diagnostics plans to initiate live
patient testing of cardiac patients at cardiac clinics in Los Angeles County,
California.
